Health and Healthcare

Health and Healthcare Articles

"Inaccurate or delayed diagnoses are the most catastrophic and costly of medical errors and will affect most of us in our lifetimes." So says the Society to Improve Diagnosis in Medicine.
While this company is unknown by many investors, one analyst believes that this could be even better than a double-your-money call.
UnitedHealth reported its second-quarter financial results before the markets opened on Thursday.
This weekend will be a real scorcher in two-thirds of the United States. Some cities have already set up cooling stations to prevent serious consequences, including heat stroke and heat exhaustion.
A major heat wave will hit two-thirds of the United States this weekend and may come with potentially very serious consequences, including heat stroke and heat exhaustion.
Johnson & Johnson shares took a hit after earnings, but it was more than just the earnings and guidance to blame. Some rivals may have been winning at the company's expense.
AvroBio shares continued their run on Wednesday, despite the firm announcing that it would be conducting a secondary offering.
Inovio Pharma shares dipped on Wednesday after the company said that it was taking measures to cut costs and its overall burn rate. When a company says it’s cutting costs one thing it can mean is...
Johnson & Johnson shares traded lower despite beating earnings. It turns out that there are some issues outside of earnings that shareholders are having a hard time quantifying.
24/7 Wall St. has picked a few biotech standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Johnson & Johnson retreated though it reported better than expected second-quarter before the markets opened on Tuesday.
Gilead and Galapagos each saw shares shoot up on Monday after the companies announced a new collaboration.
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday.
Capricor Therapeutics shares more than doubled on Monday after the firm announced interim analysis for its Duchenne muscular dystrophy midstage trial.
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.